SEARCH

SEARCH BY CITATION

References

  • Almeida AMF (2000) Análise do cariótipo eletroforético de diferentes amostras de Cryptococcus neoformans e correlação com suscetibilidade a drogas antifúngicas. MSc. Thesis, Universidade Estadual Paulista, Araraquara, SP, Brasil.
  • Barchiesi F, Hollis RJ, Messer SA, Scalise G, Rinaldi MG & Pfaller MA (1995) Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. Diagn Microbiol Infect Dis 23: 99103.
  • Barreto de Oliveira MT, Boekhout T, Theelen B, Hagen F, Baroni FA, Lazera MS, Lengeler KB, Heitman J, Rivera IN & Paula CR (2004) Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. J Clin Microbiol 42: 13561359.
  • Berg J, Clancy CJ & Nguyen MH (1998) The hidden danger of primary fluconazole prophylaxis in patients with acquired immunodeficiency syndrome. Clin Infect Dis 26: 186187.
  • Boekhout T, Van Belkum A, Leenders AC, Verbrugh HA, Mukamurangwa P, Swinne D & Scheffers WA (1997) Molecular typing of Cryptococcus neoformans, taxonomic and epidemiological aspects. Int J Syst Bacteriol 47: 432442.
  • Branchini MLM & Papaiordanou PMO (2000) Destaque para as infecções fúngicas em pacientes com Aids e no hospedeiro imunocomprometido no Brasil. J Bras AIDS 1: 3134.
  • Brandt ME, Hutwagner LC & the Cryptococcal Disease Active Surveillance Group, et al. (1996a) Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J Clin Microbiol 34: 912917.
  • Brandt ME, Pfaller MA, Hajjeh RA, Graviss EA, Rees J, Spitzer ED, Pinner RW, Meyer LW & the Cryptococcal Disease Active Surveillance Group (1996b) Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis. J Infect Dis 174: 812820.
  • Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock DW for the Cryptococcal Disease Active Surveillance Group (2001) Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992–1994 and 1996–1998. Antimicrob Agents Chemother 45: 30653069.
  • Calvo BM, Colombo AL, Fischman O, et al. (2001) Antifungal susceptibilities, varieties and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brasil, Chile, and Venezuela. J Clin Microbiol 39: 23482350.
  • Casadevall A & Perfect JR (1998) Epidemiology. Cryptococcus neoformans, pp. 351380. The American Society for Microbiology, Washington, DC.
  • Casali AK, Goulart L, Rosa e Silva LK, Ribeiro AM, Amaral AA, Alves SH, Schrank A, Meyer W & Vainstein MH (2003) Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res 3: 405415.
  • Colombo AL, Barchiesi F, McCough DA & Rinaldi MG (1995) Comparison of E-test and National Committee for Clinical Laboratory Standards broth macrodiluition method for azole antifungal susceptibility testing. J Clin Microbiol 33: 535540.
  • Cuenca-Estrella M & Rodriguez-Tudela JL (2002) Should antifungal treatments be based upon results of antifungal susceptibility testing? Rev Iberoam Micol 19: 133138.
  • Currie BP, Ghannoum M, Bessen L & Casadevall A (1995) Decreased fluconazole susceptibility of a relapse Cryptococcus neoformans isolate after fluconazole treatment. Infect Dis Clin Pract 4: 318319.
  • Delgado AC, Taguchi H, Mikami Y, Myiajy M, Villares MC & Moretti ML (2005) Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas. Mycopathologia 159: 711.
  • Franzot SP & Hamdan JS (1996) In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother 40: 822824.
  • Franzot SP, Hamdan JS, Currie BP & Casadevall A (1997) Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol 35: 22432251.
  • Franzot SP, Mukherjee J, Cherniak R, Chen LC, Hamdan JS & Casadevall A (1998) Microevolution of a standard of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun 66: 8997.
  • Fries BC & Casadevall A (1998) Serial isolates of Cryptococcusneoformans from patients with AIDS differ in virulence for mice. J Infect Dis 178: 17611766.
  • Fries BC, Chen F, Currie BP & Casadevall A (1996) Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol 34: 15311534.
  • Friese G, Discher T, Fussle R, Schmalreck A & Lohmeyer J (2001) Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 15: 23442345.
  • Horta JA, Staats CC, Casali AR, Ribeiro AM, Schrank IS, Schrank A & Vainstein MH (2002) Epidemiological aspects of clinical and environmental Cryptocococcus neoformans isolates in the Brazilian state Rio Grande do Sul. Med Mycol 40: 565571.
  • Igreja RP, Lazera MS, Wanke B, Galhardo MC, Kidd SE & Meyer W (2004) Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro. Med Mycol 42: 229238.
  • Jain N, Wickes BL, Keller SM, Fu J, Casadevall A, Jain P, Ragan MA, Banerjee U & Fries BC (2005) Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol 43: 57335742.
  • Klepser ME & Pfaller MA (1998) Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987–1994. J Clin Microbiol 36: 36533656.
  • Kwon-Chung KJ, Wickes BL, Stockman L, Roberts GD, Ellis E & Howard HH (1992) Virulence, serotype, and molecular characteristics of environmental strains of Cryptococcus neoformans var. gattii. Infect Immun 60: 18691874.
  • Lasker B, Page LS, Lott TJ & Kobayashi GS (1992) Isolation, characterization, and sequencing of Candida albicans repetitive element 2. Gene 116: 5157.
  • Lazera MS, Cavalcanti MAS, Londero AT, Trilles L, Nishikawa MM & Wanke B (2000) Possible primary ecological niche of Cryptococcus neoformans. Med Mycol 38: 379383.
  • Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD & Gallant JE (1997) Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 24: 2834.
  • Meyer W, Castaneda A, Jackson S, Huynh M & Castaneda E and the Ibero American Cryptococcal Study Group (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189195.
  • Ministério da Saúde do Brasil (2002) Dados e pesquisa em DST e Aids. Coordenação do programa nacional de DTS/Aids. Brasília, DF.
  • Mitchell TG & Perfect JR (1995) Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8: 515548.
  • Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I & Kwon-Chung KJ (1999) Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother 43: 18561861.
  • National Committee for Clinical Laboratory Standards (NCCLS) (1997) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • National Committee for Clinical Laboratory Standards (NCCLS) (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • Nguyen MH & Yu CY (1998) In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistance Cryptococcus neoformans isolates. Antimicrob Agents Chemother 42: 471472.
  • Pappalardo MCSM (2002) Criptococose em Aids: estudo clínico e microbiológico em 35 pacientes acompanhados no Instituto de Infectologia Emílio Ribas, São Paulo, entre 1995 a 1997, MSc Thesis, Coordenação dos Institutos de Pesquisa da Secretaria da Saúde de São Paulo, São Paulo, SP.
  • Pappalardo MCSM & Melhem MSC (2003) Cryptococcosis: a review of the Brazilian experience for the disease. Rev Inst Med Trop S Paulo 45: 299305.
  • Perfect JR & Cox GM (1999) Drug resistance in Cryptococcus neoformans. Drug Resist Updat 2: 259269.
  • Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL & Cuenca-Estrella M (2005) Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56: 11441147.
  • Pfaller MA, Zhang J, Messer S, Tumberland M, Mbidde E, Jessup C & Ghannoum M (1998) Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. Diagn Microb Infect Dis 32: 191199.
  • Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV & Diekema DJ (2005) Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 43: 21632167.
  • Powderly WG, Finkelstein DM, Feinberg J, et al. (1995) A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 332: 700705.
  • Rezende C (2002) Aspectos fenotípicos e moleculares de amostras de Cryptococcus neoformans da região de Araraquara e Ribeirão Preto, relacionados aos perfis de suscetibilidade, MSc Thesis, Universidade Estadual Paulista, Araraquara, SP, Brasil.
  • Rodero L, Mellado E, Rodriguez AC, Salve A, Guelfand L, Cahn P, Cuenca-Estrella M, Davel G & Rodriguez-Tudela JL (2003) G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother 47: 36533656.
  • Rodriguez-Tudela JL, Berenguer J, Martinez-Suarez JV & Sanchez R (1996) Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrob Agents Chemother 40: 19982003.
  • Rozenbaum R & Gonçalves AJ (1994) Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 18: 369380.
  • Sanati H, Messer SA, Pfaller MA, Witt M, Larsen R, Espinel-Ingroff A & Ghannoum M (1996) Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol 34: 12801282.
  • Sar B, Monchy D, Vann M, et al. (2004) Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 54: 563565.
  • Soll DR (2000) The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev 13: 332370.
  • Sukroongreung S, Lim S, Tantimavanich S, Eampokalap B, Carter D, Nilakui C, Kulderatiyut S & Tanshyphaswadikui S (2001) Phenotypic switching and genetic diversity of Cryptococcusneoformans. J Clin Microbiol 39: 20602064.